Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Genfit is a late-stage biopharmaceutical company focused on the discovery and development of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, particularly those with high unmet medical needs. The company's primary efforts are concentrated on conditions such as Primary Biliary Cholangitis (PBC) and other liver ailments. Genfit leverages its expertise in nuclear receptor-based drug discovery and clinical development to advance its pipeline, aiming to provide impactful treatments to patients worldwide.
The Loos headquarters serves as the nerve center for Genfit's global operations, housing its primary research and development laboratories, clinical development teams, corporate administration, and strategic decision-making functions.
Located within Parc Eurasanté, a leading European life sciences and healthcare innovation park, offering state-of-the-art facilities and fostering collaboration within a rich ecosystem of research institutions and biotech companies.
Genfit promotes a collaborative, science-driven work culture focused on innovation and a commitment to addressing unmet medical needs in liver and metabolic diseases. The environment encourages scientific rigor, teamwork, and agility in advancing its therapeutic programs.
This site is crucial for Genfit's identity and operations, being the birthplace of its key drug candidates and the central point for coordinating its extensive global clinical trials and research collaborations.
Genfit maintains a global operational footprint to support its extensive research, clinical development, and future commercialization activities. Key functions supported globally include conducting multinational clinical trials across North America, Europe, and other regions; engaging with international regulatory bodies like the FDA (USA) and EMA (Europe); fostering worldwide collaborations and partnerships for drug development and commercialization; and managing investor relations on an international scale. While its R&D and corporate hub is in France, its U.S. presence is critical for market access and clinical operations.
Parc Eurasanté, 885 Avenue Eugène Avinée
Loos
Hauts-de-France
France
Address: One Broadway, 14th Floor, Cambridge, MA 02142, USA
To facilitate clinical trials in the U.S., engage with American regulatory authorities, connect with the U.S. investment community, and expand Genfit's strategic partnerships within the world's largest pharmaceutical market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, GENFIT' leadership includes:
GENFIT has been backed by several prominent investors over the years, including:
In the past year, Genfit strategically enhanced its leadership by appointing a new Chief Business Officer, aiming to bolster its business development and corporate strategy efforts as its lead drug candidates progress towards potential market authorization.
Discover the tools GENFIT uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Genfit's email format typically follows a standard corporate structure. The most common pattern observed is the employee's first initial combined with their full last name, or first name separated by a dot from their last name.
flastname@genfit.com or firstname.lastname@genfit.com
Format
jsmith@genfit.com or john.smith@genfit.com
Example
80%
Success rate
GlobeNewswire • May 2, 2024
GENFIT reported its cash position, revenues, and operating expenses for Q1 2024, alongside updates on its key programs including elafibranor for PBC and GNS561 for cholangiocarcinoma. The company highlighted the upcoming PDUFA date for elafibranor in June 2024....more
GlobeNewswire • April 8, 2024
Genfit announced multiple presentations at the EASL Congress 2024, showcasing new data on elafibranor in PBC and other research in ACLF and liver diseases, reinforcing its scientific contributions to the field....more
GlobeNewswire • February 15, 2024
Genfit announced the publication of pivotal Phase 3 ELATIVE™ trial results for elafibranor in PBC in the prestigious New England Journal of Medicine, underscoring the drug's efficacy and safety profile and its potential as a new treatment option for this chronic liver disease....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including GENFIT, are just a search away.